The reversal of multidrug resistance: An update

Journal of Experimental Therapeutics and Oncology

Volumn 3, Issue 1, 2003, Pages 5-13

  Kellen, John A ^a,b  

^a UNIVERSITY OF TORONTO   (Canada)

^b NONE   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

5 [3 (4 DIPHENYLACETYL 1 PIPERAZINYL) 2 HYDROXYPROPOXY]QUINOLINE; ACRIDINE DERIVATIVE; AMITRIPTYLINE; APHIDICOLIN; AUREOBASIDIN A; BROMOCRIPTINE; BRYOSTATIN; CAFFEIC ACID; CANAVANINE; CANNABINOL; CEPHARANTHINE; CHALCONE DERIVATIVE; CYCLOSPORIN DERIVATIVE; CYTOCHROME P450; CYTOCHROME P450 3A4; CYTOCHROME P450 3A5; ELACRIDAR; FLAVOPIRIDOL; FLUPENTIXOL; GENISTEIN; GLYCOPROTEIN P; MIDOSTAURIN; OMEPRAZOLE; PENTOXIFYLLINE; PHENOTHIAZINE DERIVATIVE; PHENOXAZINE DERIVATIVE; RITONAVIR; TAXOID; UNINDEXED DRUG; ZOSUQUIDAR;

ANIMAL CELL; CANCER CELL; DNA MICROARRAY; DRUG SENSITIVITY; DRUG TRANSPORT; EXCISION REPAIR; FLOW CYTOMETRY; HUMAN; HUMAN CELL; MULTIDRUG RESISTANCE; MUTATION RATE; NONHUMAN; NORTHERN BLOTTING; PLEIOTROPY; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; REVIEW;

ANIMALS; ANTINEOPLASTIC AGENTS; DRUG RESISTANCE, MULTIPLE; DRUG RESISTANCE, NEOPLASM; HUMANS; NEOPLASMS;

EID: 0038072903     PISSN: 13594117     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1359-4117.2003.01067.x     Document Type: Review

References (95)

1. Krishna R, Mayer LD. Multidrug resistance (MDR) in cancer. Eur J Pharm Sci 11: 265-283, 2000.
2. Robert J. Multidrug resistance in oncology: diagnostic and therapeutic approaches. Eur J Clin Invest 29: 536-545, 1993.
3. Karaszi E, Jakab K, Homolya L, et al. Calcein assay for multidrug resistance reliable predicts therapy response and survival rate in acute myeloid leukemia. Br J Haematol 112: 308-314, 2001.
4. Wang EJ, Casciano CN, Clement RP, et al. In vitro flow cytometry method to quantitatively assess inhibitors of P-glycoprotein. Drug Metab Dispos 28: 522-526, 2000.
5. Litman T, Druley TE, Stein WD, et al. From MDP, to MXR: new understanding of multidrug resistance systems, their properties and clinical significance. Cell Mol Life Sci 58: 931-959, 2001.
6. Bontemps-Gracz MM, Kupiec A, Antonini I, et al. The ability to overcome multidrug resistance of tumor cells with novel acridine cytostatics. Acta Biochim Pol 49: 87-92, 2002.
7. Szabo D, Szabo G, Ocsovszki I, et al. Anti-psychotic drugs reverse multidrug resistance of tumor cell lines and human AML cells ex-vivo. Cancer Lett 139: 115-119, 1999.
8. Moreland NJ, Illand M, Kim UT, et al. Modulation of drug resistance mediated by loss of mismatch repair by aphidicolin. Cancer Res 59: 2102-2106, 1999.
9. Rao VV, Herman LW, Kronauge JF, et al. A novel areneisonitrile TC complex inhibits the transport activity of MDR P-glycoprotein. Nucl Med Biol 25: 225-232, 1998.
10. Morihira K, Nishimori T, Kusama H, et al. Synthesis of C-ring aromatic taxoids and evaluation of their multidrug resistance reversing activity. Bioorg Med Chem Lett 8: 2973-2976, 1998.
11. Boyd RA, Stern RH, Steart Bh, et al. Atorvastatin coadministration may increase digoxin concentrations by inhibition of intestinal P-glycoprotein mediated secretion. J Clin Pharmacol 40: 91-98, 2000.
12. Kurome T, Takesako K, Kato I. Aureobasidins as new inhibitors of P-glycoprotein in multidrug resistant tumor cells. J Antibiot 51: 353-358, 1998.
13. Mendez-Vidal C, Quesada AR. Reversal of P-glycoprotein-mediated multidrug resistance in vitro by AV200, a new ardeemin derivative. Cancer Lett 132: 45-50, 1998.
14. Sankaran B, Bhagat S, Senior AE. Inhibition of P-glycoprotein ATPase activity by beryllium fluoride. Biochemistry 36: 6847-6853, 1997.
15. Horton JK, Thimmaiah KN, Altenberg GA, et al. Characterization of a novel bisacridone and comparison with PSC 833 as a potent and poorly reversible modulator of P-glycoprotein. Mol Pharmacol 52: 948-957, 1997.
16. Demetri GD. Clinical studies of VX-710 (Biridocar, Incel), a small molecule inhibitor of the MDR-1 and MRP drug efflux pumps. Chemotherapy Foundation Symposium XVII, November 3-6, 1999, New York, NY, p. 66 (Abstract 51).
17. Tian H, Pan Q-C. Modulation of multidrug resistance by three bisbenzyl-isoquinolines in comparison with verapamil. Acta Pharmacol Sin 18: 455-458, 1997.
18. Orlowski S, Valente D, Garrigos M, et al. Bromocriptine modulates P-glycoprotein Function. BBRC 244: 481-488, 1998.
19. Spitaler M, Utz I, Hilbe W, et al. PKC-independent modulation of multidrug resistance in cells with mutant (V185) P-glycoprotein by Bryostatin 1. Biochem Pharmacol 56: 861-869, 1998.
20. Ahn C-C, Choi WC, Kong JY. Chemosensitizing activity of caffeic acid in multidrug-resistant MCF-7/Dox human breast carcinoma cells. Anticancer Res 17: 1913-1918, 1997.
21. Molnar J, Szabo D, Berek L, et al. Multidrug resistance reversal in tumor cells by some cannabis, ginzenizide and saffrone derivatives. Sixth International Conference on Anticancer Research, October 1998, Kallithea, Greece (Abstract 218).
22. Hotta T, Tanimura H, Yamaue H, et al. Modulation of multidrug resistance by cepha-rantine in fresh human gastrointestinal tumor cells. Oncology 54: 153-157, 1997.
23. Ras F, Garcia R, Gallego P, et al. Synthesis of a series of 3-cyanopropionamides and evaluation of their function as modulators of multidrug resistance. Arch Pharm Med Chem 333: 329-336, 2000.
24. Demeule M, Laplante A, Sepher-Arae A, et al. Inhibition of P-glycoprotein by cyclosporin A analogues and metabolites. Biochem Cell Biol 77: 47-58, 1999.
25. Hwang BY, Kim SE, Kim YH, et al. Pregnane glycoside multi-drug-resistance modulators from Cynanchum wilfordii. J Nat Prod 62: 640-643, 1999.
26. Andrus MB, Lepore SD. Synthesis of Stipamide and a new multidrug resistance reversal agent, 6,7-dehydrostipamide. J Am Chem Soc 119: 2327-2328, 1999.
27. Imai Y, Tsukahara S, Shikawa E, et al. Estrone and 17beta-estradiol reverse breast cancer resistance. Jpn J Cancer Res 93: 231-235, 2002.
28. Dietel M, Boss H, Reymann A, et al. In vivo reversibility of multidrug resistance by the MDR-modulator dexniguldipine. J Exp Ther Oncol 1: 23-29, 1996.
29. Tanabe H, Tasaka S, Ohmori H, et al. Newly synthesized dihydropyridine derivatives as modulators of P-glycoprotein-mediated multidrug resistance. Bioorg Med Chem 6: 2219-2227, 1998.
30. Curtin NJ, Turner DP. Dipyridamole-mediated reversal of multidrug resistance in MRP overexpressing human lung carcinoma cells in vitro. Eur J Cancer 35: 1020-1026, 1999.
31. Hooijberg JH, Broxterman HJ, Scheffer GL, et al. Potent interaction of flavopiridol with MRP1. Br J Cancer 8: 269-276, 1999.
32. Wiese M, Pajeva IK. Molecular modeling study of the multidrug resistance modifiers cis- and trans-flupentixol. Pharmazie 52: 679-685, 1997.
33. Jonsson O, Behnam-Motlagh P, Persson M, et al. Increase in doxorubicin cytotoxicity by carvedilol inhibition of P-glycoprotein activity. Biochem Pharmacol 58: 1801-1806, 1999.
34. Castro AT, Altenberg GA. Inhibition of drug transport by genistein. Biochem Pharmacol 53: 89-93, 1997.
35. Sparreboom A, Planting AST, Jewell RC, et al. Clinical pharmacokinetics of doxorubicin in combination with GF120918, a potent inhibitor of MDR1 P-glycoprotein. Anticancer Drugs 10: 719-728, 1999.
36. Chiba P, Rebitzer S, Richter E, et al. Synthesis and pharmacological activity of the stereoisomers of GP-88, a propafenone-type modulator of multidrug resistance. Bioorg Med Chem Lett 8: 829-832, 1998.
37. Bois F, Beney Ch, Boumendjel A, et al. Halogenated chalcones with high-affinity binding to P-glycoprotein. J Med Chem 41: 4161-4164, 1998.
38. Veldman RJ, Sietsma H, Klappe K, et al. Inhibition of P-glycoprotein activity and chemosensitization of ovarian carcinoma 2780AD Cells by hexanoylglucosylceramide. BBRC 266: 492-496, 1999.
39. Tambur AR, Markham PN, Gebel HM. IL-4 inhibits P-glycoprotein in normal and malignant NK cells. Hum Immunol 59: 483-487, 1998.
40. Naito S, Koike K, Ono M, et al. Development of novel reversal agents, imidazothiazole derivatives, targeting MDR1 and MRP-mediated multidrug resistance. Oncol Res 10: 123-132, 1998.
41. Kam T-S, Subramaniam G, Sim K-M, et al. Reversal of multidrug resistance by aspidofractinine-type indole alkaloids. Bioorg Med Chem Lett 8: 2769-2772, 1998.
42. Rho M-C, Toyoshima M, Hayasho M, et al. Reversal of multidrug resistance by kopsiflorine. Planta Med 65: 307-310, 1999.
43. Iida N, Takara K, Ohmoto N, et al. Reversal effects of antifungal drugs on multidrug resistance. Biol Pharm Bull 24: 1032-1036, 2001.
44. Choi SU, Lee BH, Kim KH, et al. Novel multidrug-resistance modulators, KR-30026 and KR-30031, in cancer cells. Anticancer Res 17: 4577-4582, 1997.
45. Worthen DR, Chien L, Tsuboi CP. L-Canavanine modulates cellular growth, chemosensitivity and P-glycoprotein substrate accumulation in cultured human cells. Cancer Lett 132: 229-239, 1998.
46. Sharom FJ, Lu P, Liu R. Linear and cyclic peptides as substrates and modulators of P-glycoprotein: peptide binding and effects on drug transport and accumulation. Biochem J 333: 621-630, 1998.
47. Norman BH, Dantzig AH, Kroin JS. Reversal of resistance in multidrug resistant protein (MRP)-overexpressing cells by LY329146. Bioorg Med Chem Lett 9: 3381-3386, 1999.
48. Dantzig AH, Law KL, Cao J. Reversal of multidrug resistance by the P-glycoprotein modulator LY335979, from the bench to the clinic. Curr Med Chem 8: 39-50, 2001.
49. Trindade GS, Farias SLA, Rumianek VM, et al. Methylene blue reverts multidrug resistance. Cancer Lett 151: 161-167, 2000.
50. Kimura Y, Aoki J, Kohno M, et al. P-Glycoprotein inhibition by the multidrug resistance-reversing agent MS-209. Cancer Chemother Pharmacol 49: 322-328, 2002.
51. Teodori E, Dei S, Garnier-Suillerot A, et al. Structure-activity relationship studies on the potent MDR modulator MM36. Med Chem Res 10: 563-576, 2001.
52. Boger DL, Soenen DR, Boyce CW, et al. Total synthesis of ningalin B and discovery of a new class of potent MDR reversal agents. J Org Chem 65: 2479-2483, 2000.
53. Charuk JHM, Grey AA, Reithmeier RAF. Identification of the synthetic surfactant nonylphenol ethoxylate: a P-glycoprotein substrate in human urine. Am J Physiol 274: F1127-F1139, 1999.
54. Drobna Z, Stein U, Walther W, et al. Pentoxifylline influences drug transport activity of P-glycoprotein and decreases mdr1 gene expression. Gen Physiol Biophys 21: 103-109, 2000.
55. Newman MJ, Rodarte JC, Benbatoul KD, et al. Discovery and characterization of OC144-093, a novel inhibitor of P-glycoprotein-mediated multidrug resistance. Cancer Res 60: 2964-2972, 2000.
56. Vanhoefer U, Muller MR, Hilger RA, et al. Reversal of MDR1-associated resistance to topotecan by PAK-200S, a new dihydropyridine analogue, in human cancer cell lines. Br J Cancer 81: 1304-1310, 1999.
57. Batrakova EV, Li S, Emquist WF, et al. Mechanism of senzitisation of MDR cancer cells by Pluronic block copolymers. Br J Cancer 85: 1987-1997, 2001.
58. Pajeva IK, Wiese M. QSAR and molecular modeling of catamphilic drugs able to modulate multidrug resistance in tumors. Quant Struct Activity Relat 16: 1-10, 1997.
59. 10-substituted phenoxazines for reversing MDR in cancer cells. Oncology Res 10: 29-41, 1998.
60. de Verdiere AC, Dubernet C, Nemati F, et al. Reversion of multidrug resistance with polyalkylcyanoacrylate nanoparticles. Br J Cancer 76: 198-205, 1997.
61. Andrus MB, Turner TM, Sauna ZE, et al. The synthesis and evaluation of a solution phase indexed combinatorial library of non-natural polyenes for reversal of P-glycoprotein mediated MDR. J Org Chem 65: 4973-4983, 2000.
62. Chiba P, Annibali D, Hitzler M, et al. Studies on propafenone-type modulators of multidrug resistance. II Farmaco 53: 357-364, 1998.
63. Cabot MC, Giuliano AE, Han T-Y, et al. SDZ PSC 833, the cyclosporine A analogue and multidrug resistance modulator activates ceramide synthesis and increases vinblastine sensitivity in drug-sensitive and drug-resistant cancer cells. Cancer Res 59: 880-885, 1999.
64. Sharom FJ, Yu X, Lu P, et al. Interaction of the P-glycoprotein multidrug transporter (MDR1) with high affinity peptide chemosensitizers in isolated membranes, reconstituted systems and intact cells. Biochem Pharmacol 58: 571-586, 1999.
65. Drewe J, Gutman H, Fricker G, et al. IV protease inhibitor Ritonavir: a more potent inhibitor of P-glycoprotein than the cyclosporine analogue SDZ PSC 833. Biochem Pharmacol 57: 1147-1152, 1999.
66. Yin M-B, Guo B, Voigt W, et al. Novel cellular determinants for reversal of multidrug resistance in cells expressing P170-glycoprotein. BBA 1401: 265-276, 1998.
67. Plouzek CA, Ciolino HP, Clarke R, et al. Inhibition of P-glycoprotein activity and reversal of MDR in vitro by rosemary extract. Eur J Cancer 35: 1541-1545, 1999.
68. Tranchand B, Catimel G, Lucas C, et al. Phase I clinical and pharmacokinetic study of S9788: a new multidrug-resistance reversal agent. Cancer Chemother Pharmacol 41: 281-291, 1998.
69. Kurosawa K, Takahashi K, Tsuda E, et al. Reversal of multidrug resistance by novel nitrophenyl pyrones SNF4435C and D. Jpn J Cancer Res 92: 1235-1241, 2001.
70. Pierre A, Leonce S, Perez V, et al. Circumvention of P-glycoprotein-mediated multidrug resistance by S16020-2. Cancer Chemother Pharmacol 42: 454-460, 1998.
71. Utz I, Spitaler M, Rybczynska M, et al. Reversal of MDR by the staurosporine derivatives CGP 41251 and CGP 42700. Int J Cancer 77: 64-69, 1998.
72. Hall AM, Chang C-J. Multidrug-resistance modulators from stephania japonica. J Nat Prod 60: 1193-1195, 1997.
73. Ojima I, Bounaud P-Y, Takeuchi C, et al. New taxanes as highly efficient reversal agents for multidrug resistance in cancer cells. Bioorg Med Chem Lett 8: 189-194, 1998.
74. Sako M, Suzuki H, Hirota K. Syntheses of Taxuspine C derivatives as functional inhibitors of P-glycoprotein. Chem Pharm Bull (Tokyo) 46: 1135-1139, 1998.
75. Qi J, Yang C-Z, Wang C-Y, et al. Function and mechanism of pyronaradine: a new inhibitor of P-glycoprotein. Acta Pharmacol Sin 23: 544-550, 2002.
76. Baggetto LG, Dong M, Bernaud J, et al. In vitro and in vivo reversal of cancer cell multidrug resistance by the semi-synthetic antibiotic Tiamulin. Biochem Pharmacol 56: 1219-1228, 1998.
77. Kim SE, Kim YH, Kim YC, et al. Torilin, a sesquiterpene from Torilis japonica, reverses MDR in cancer cells. Planta Med 64: 332-334, 1998.
78. Nanaumi K, Tsuchida K, Nakaike S, et al. Overcoming of multidrug resistance by VA-033, a novel derivative of aponvincaminic acid ester. Eur J Pharmacol 327: 239-246, 1997.
79. Pauli-Magnus Ch, Rekersbrink S, Klotz U, et al. Interaction of omeprazole, lansoprazole and pantoprazole with P-glycoprotein. Naunyn Schmiedebergs Arch Pharmacol 364: 551-557, 2001.
80. Jodoin J, Demeule M, Beliveau R. Inhibition of the multidrug resistance P-glycoproein activity by green tea polypenols. BBA 1542: 149-159, 2000.
81. Wang S, Ryder H, Pretswell H, et al. Studies on quinazolinones as dual inhibitors of Pgp and MRP1 in multiple resistance. Bioorg Med Chem Lett 12: 571-574, 2000.
82. Hohman J, Molnar J, Redei D, et al. Reversal of multidrug resistance of mouse lymphoma cells by a new, natural jatropane diterpenoid. J Med Chem 45: 2425-2431, 2002.
83. Roe M, Folkes A, Ashworth P, et al. Reversal of P-glycoprotein mediated multidrug resistance by novel anthranilamide derivatives. Bioorg Med Chem Lett. 9: 595-600, 1999.
84. Mistry P, Stewart AJ, Dangerfield W, et al. In vitro and in vivo reversal of P-glycoprotein-mediated multidrug resistance by a novel potent modulator, XR9576. Cancer Ras 61: 749-675, 2001.
85. Reynolds T. Outwitting drug resistance requires researchers to take many tacks. J Natl Cancer Inst 90: 1186-1188, 1998.
86. Brown R. Cisplatin resistance in ovarian cancer: mismatch repair and engagement of apoptosis. In: Hickman JA, Dive C, eds. Apoptosis and Chemosensitivity. Totowa, NJ: Humana Press. 69-86, 1999.
87. Arancia G, Molinari A, Calcabrini A, et al. Intracellular P-glycoprotein in multidrug resistant tumor cells. Ital J Anat Embryol 106: 59-68, 2001.
88. Castaign M, Loiseau A, Dani M. Thermal dependence of multidrug-resistant modulator efficiency. J Pharm Pharmacol 52: 1171-1178, 2000.
89. Tunggal JK, Ballinger JR, Tannock IF. Influence of cell concentration in limiting the therapeutic benefit of P-glycoprotein reversal agents. Int J Cancer 81: 741-747, 1999.
90. Loo TW, Clarke DM. The human MDR P-glycoprotein is inactive when its maturation is inhibited. FASEB J 13: 1724-1732, 1999.
91. van de Waterbeemd H. Role of human CYP3A and P-glycoprotein in the adsorbtion of drugs. Eur J Pharm Sci 12: 1, 2000.
92. Rimsza LM, Campbell K, Dalton WS, et al. The major vault protein (MVP), a new multidrug resistance associated protein. Leuk Lymphoma 34: 315-324, 1999.
93. Miller M. Is there less resistance on the chemoresistance front? JNCI 94: 15-16, 2002.
94. Kim RB. Drugs as P-glycoprotein substrates, inhibitors and inducers. Drug Metab Rev 34: 47-54, 2002.
95. Karp JE, Mookerjee BP. Overcoming drug resistance: targeting more than one site. Leuk Res 26: 107-109, 2002.